Clinical Trial: NCT04022343
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Emory University |
| Information Provided By: | Emory University |
| Last Update Posted: | 2026-05-05 |
Study Overview
Brief Summary
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Official Title
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Intervention / Treatment
- Drug: Cabozantinib
Other Study ID Numbers
- IRB00110583
- NCI-2019-02253
- Winship4643-19
- P30CA138292
Start Date (Actual)
2019-08-06
Primary Completion Date (Actual)
2022-02-02
Study Completion Date (Estimated)
2026-12-09
Enrollment (Actual)
22
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Emory University |
| Information Provided By: | Emory University |
| Last Update Posted: | 2026-05-05 |
Study Overview
Brief Summary
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Official Title
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Intervention / Treatment
- Drug: Cabozantinib
Other Study ID Numbers
- IRB00110583
- NCI-2019-02253
- Winship4643-19
- P30CA138292
Start Date (Actual)
2019-08-06
Primary Completion Date (Actual)
2022-02-02
Study Completion Date (Estimated)
2026-12-09
Enrollment (Actual)
22
Study Type
Interventional
Phase
Phase 2